Masahiko Fujioka

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Shionogi Company Limited. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiko Fujioka. Retrieved from https://idiyas.com/inventor/masahiko-fujioka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 19(Granted Patents)

Company Filing History:

6 out of 1,001

Shionogi Company Limited

patents

Years Active: 2012-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10093670 - Azabenzimidazole derivative having AMPK-activating activity (2018-10-09),

2. 9567330 - Azabenzimidazole derivative having AMPK-activating activity (2017-02-14),

3. 9440938 - Sulfonamide derivative having PGD2 receptor antagonistic activity (2016-09-13),

4. 9133186 - Hetero ring-fused imidazole derivative having AMPK activating effect (2015-09-15),

5. 8993763 - Sulfonamide derivative having PGD2 receptor antagonistic activity (2015-03-31),

6. 8153793 - Sulfonamide derivative having PGD2 receptor antagonistic activity (2012-04-10),

Title: Masahiko Fujioka: Innovator in AMPK-Activating Compounds

Introduction

Masahiko Fujioka is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that activate AMP-activated protein kinase (AMPK). With a total of 6 patents to his name, Fujioka's work is recognized for its potential impact on metabolic diseases.

Latest Patents

Among his latest innovations, Fujioka has developed an azabenzimidazole derivative that exhibits AMPK-activating activity. This compound is disclosed as being useful as an AMPK activator, which could have important implications for treating various health conditions. The specific formula of the compound, or its pharmaceutically acceptable salt, highlights the innovative nature of his research.

Career Highlights

Fujioka is currently associated with Shionogi & Company Limited, a well-respected pharmaceutical company. His role at Shionogi allows him to further his research and development efforts in the pharmaceutical sector, contributing to advancements in medical science.

Collaborations

Fujioka has collaborated with notable colleagues, including Akira Kugimiya and Yuki Tachibana. These partnerships have likely enhanced the scope and impact of his research, fostering a collaborative environment for innovation.

Conclusion

Masahiko Fujioka's work in developing AMPK-activating compounds positions him as a key figure in pharmaceutical innovation. His contributions are paving the way for new treatments that could benefit many individuals suffering from metabolic disorders.

Profile summary based on public USPTO records.